Bristol-Myers Squibb and Gilead Sciences announced today that the U.S. Food and Drug Administration (FDA) has given clearance for them to begin selling Atripla, the long-awaited tablet containing Sustiva (efavirenz) and Truvada (tenofovir and emtricitabine). Atripla is the first one-pill, once-daily complete anti-HIV drug regimen to be approved by the FDA.

Other links:
Treatment News Story
POZ Atripla Drug Information Page